Brain metastases (BMs) occur in 10% to 20% of adult patients with cancer, and with
increased surveillance and improved systemic control, the incidence is likely to grow …

Brain metastases occur in 20–40% of patients with cancer and their frequency has
increased over time. Lung, breast and skin (melanoma) are the commonest sources of brain …

Brain metastases are an important sequelae of many types of cancer, most commonly lung
cancer. Current treatment options include whole-brain radiation therapy (WBRT), surgical …

As systemic cancer therapies improve and are able to control metastatic disease outside the
central nervous system, the brain is increasingly the first site of relapse. The blood–brain …

This review focuses on the management of brain metastases. The four main modes of
therapy are discussed: whole brain radiation therapy (WBRT), surgery, radiosurgery, and …

Background: Standard salvage therapy has not been established for recurrent primary
central nervous system lymphoma (PCNSL). We report the final results of a prospective …

Most small cell lung cancer (SCLC) patients relapse within 12 months of starting
combination chemotherapy plus radio-therapy, due to the development of acquired chemo …

Objectives To assess if the combination of topotecan, paclitaxel, and bevacizumab (TPB)
was active in recurrent SCCC and to compare the survival of patients with SCCC who …

Purpose The purpose of this study was to investigate the radiologic response of
asymptomatic brain metastases (BM) from small-cell lung cancer (SCLC) to first-line …

The purpose of this multicentre phase II study was to evaluate the efficacy and toxicity of
topotecan in pretreated patients with small-cell lung cancer (SCLC) who relapsed with …